, Volume 9, Issue 1, pp 1–4 | Cite as

Noncompliance with Antihypertensive Therapy

Economic Consequences
  • Tracy L. Skaer
  • David A. Sclar
  • Linda M. Robison
Current Opinion


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks: US population data. Arch Intern Med 1993; 153: 598–615PubMedCrossRefGoogle Scholar
  2. 2.
    Sever P, Beevers G, Bulpitt C, et al. Management guidelines in essential hypertension: report of the Second Working Party of the British Hypertension Society. BMJ 1993; 306: 983–7PubMedCrossRefGoogle Scholar
  3. 3.
    Guidelines Subcommittee of the WHO/ISH Mild Hypertension Liaison Committee. 1993 guidelines for the management of mild hypertension: memorandum from a World Health Organization/International Society of Hypertension meeting. Hypertension 1993; 22: 392–403CrossRefGoogle Scholar
  4. 4.
    Myers MG, Carruthers SG, Leenen FHH, et al. Recommendations from the Canadian Hypertension Society Consensus Conference on the pharmacologic treatment of hypertension. Can Med Assoc J 1989; 140: 1141–6Google Scholar
  5. 5.
    Hypertension Guidelines Committee, South Australian Faculty, Royal Australian College of General Practitioners. Hypertension: diagnosis, treatment, and maintenance. Guidelines endorsed by the High Blood Pressure Research Council ofAustralia. Adelaide: South Australian Faculty, Royal Australian College of General Practitioners, 1991Google Scholar
  6. 6.
    Mild hypertension: a summary of the 1993 World Health Organization/International Society of Hypertension (WHO/ISH) guidelines for the management of mild hypertension. Memorandum from a WHO/ISH meeting. J Intern Med 1994; 235:21–97CrossRefGoogle Scholar
  7. 7.
    Herbert PR, Moser M, Mayer J, et al. Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease. Arch Intern Med 1993; 153: 578–81CrossRefGoogle Scholar
  8. 8.
    SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 1991; 265: 3255–64CrossRefGoogle Scholar
  9. 9.
    Trials of Hypertension Prevention Collaborative Research Group. The effects of nonpharmacologic interventions of blood pressure of persons with high normal levels: results of the Trials of Hypertension Prevention, Phase I. JAMA 1992; 267: 1213–20CrossRefGoogle Scholar
  10. 10.
    Treatment of Mild Hypertension Research Group. The treatmentof mild hypertension study: a randomized, placebocontrolled trial of a nutritional-hygienic regimen along with various drug monotherapies. Arch Intern Med 1992; 152: 131–6CrossRefGoogle Scholar
  11. 11.
    Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC-V). Arch Intern Med 1993; 153: 154–83CrossRefGoogle Scholar
  12. 12.
    Pardell H, Armario P, Hernandez R. Progress in the 1980s and new directions in the 1990s with hypertension management: from the stepped-care approach to the individualised programme in hypertension treatment and control. Drugs 1992; 43 (1): 1–5PubMedCrossRefGoogle Scholar
  13. 13.
    Alderman MH. Which antihypertensive drugs first - and why? JAMA 1992; 267: 2786–7PubMedCrossRefGoogle Scholar
  14. 14.
    Stason WB. Opportunities to improve the cost-effectiveness of treatment for hypertension. Hypertension 1991; 18 Suppl. 3: 1161–6CrossRefGoogle Scholar
  15. 15.
    Levine DM, Bone L. The impact of a planned health education approach on the control of hypertension in a high risk population. J Hum Hypertens 1990; 4: 317–21PubMedGoogle Scholar
  16. 16.
    Balazovjech I, Hnilica Jr P. Compliance with antihypertensive treatment in consultation rooms for hypertensive patients. J Hum Hypertens 1993; 7 (6): 581–3PubMedGoogle Scholar
  17. 17.
    Col N, Fanale JE, Kronholm P. The role of medication noncompliance and adverse drug reactions in hospitalizations of the elderly. Arch Intern Med 1990; 150: 841–5PubMedCrossRefGoogle Scholar
  18. 18.
    Sclar DA, Skaer TL, Chin A, et al. Utility of a transdermal delivery system for antihypertensive therapy: part II. Am J Med 1991; 91 Suppl. 1A: 57S-60SCrossRefGoogle Scholar
  19. 19.
    McCombs JS, Nichol MB, Newman CM, et al. The costs of interrupting antihypertensive drug therapy in a medicaid population. Med Care 1994; 32: 214–26PubMedCrossRefGoogle Scholar
  20. 20.
    Office of National Cost Estimates. National health care expenditures, 1988 [summary]. Health Care Financ Rev 1990; 11: 125Google Scholar
  21. 21.
    Carney S, Gillies A, Smith A, et al. Hypertension education: patient knowledge and satisfaction. J Hum Hypertens 1993; 7 (5): 505–8PubMedGoogle Scholar
  22. 22.
    Sharkness CM, Snow DA. The patient’s view of hypertension and compliance. Am J Prev Med 1992; 8 (3): 141–6PubMedGoogle Scholar
  23. 23.
    Richardson MA, Simons-Morton B, Annegers JE Effect of perceived barriers on compliance with antihypertensive medication. Health Educ Q 1993; 20 (4): 489–503PubMedCrossRefGoogle Scholar
  24. 24.
    Eisen SA, Miller DK, Woodward RS, et al. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990; 150: 1881–4PubMedCrossRefGoogle Scholar
  25. 25.
    Farquhar JW, Fortmann SP, Flora JA, et al. Effects of communitywide education on cardiovascular disease risk factors: the Stanford five-city project. JAMA 1990; 264: 359–65PubMedCrossRefGoogle Scholar
  26. 26.
    Lefebvre RC, Lasater TM, Carleton RA, et al. Theory and delivery of health programming in the community: the Pawtucket Heart Health Program. Prev Med 1987; 16: 80–95PubMedCrossRefGoogle Scholar
  27. 27.
    Sawicki PT, Muhlhauser I, Didjurgeit U, et al. Improvement ofhypertension care by a structured treatment and teaching programme. J Hum Hypertens 1993; 7 (6): 571–3PubMedGoogle Scholar
  28. 28.
    Bittar N. Maintaining long-term control of blood pressure: the role of improved compliance. Clin Cardiol 1995; 18 Suppl. 3: 312–6CrossRefGoogle Scholar
  29. 29.
    ScIar DA, Tessier GC, Skaer TL, et al. Effect of pharmaceutical formulation of diltiazem on medicaid and health maintenance organization services. Curr Ther Res 1994; 55 (10): 1136–49CrossRefGoogle Scholar
  30. 30.
    Webber GC. Patient education: a review of the issues. Med Care 1990; 28 (11): 1089–103PubMedCrossRefGoogle Scholar
  31. 31.
    Skaer TL, Sclar DA, Markowski DJ, et al. Effect of value-added utilities on prescription refill compliance and health care expenditures for hypertension. J Hum Hypertens 1993; 7 (5): 515–8Google Scholar
  32. 32.
    Sclar DA, Skaer TL, Chin A, et al. Effect of health education on the utilization of HMO services: a prospective trial among patients with hypertension. Prim Cardiol 1992; 18 Suppl. 1: 30–5Google Scholar
  33. 33.
    Vogel DP. Patient-focused care. Am J Hosp Pharm 1993; 50: 2321–9PubMedGoogle Scholar
  34. 34.
    Lathrop JP. Patient-focused care in theory and action. Am J Health Syst Pharm 1995; 52: 45–8PubMedGoogle Scholar
  35. 35.
    Shea S, Misra D, Enrlich MH, et al. Correlates of nonadherence to hypertension treatment in an inner-city minority population. Am J Public Health 1992; 82: 1607–12PubMedCrossRefGoogle Scholar
  36. 36.
    Francis CK. Hypertension, cardiac disease, and compliance in minority patients. Am J Med 1991; 91 Suppl.1A: 29S-36SCrossRefGoogle Scholar
  37. 37.
    Clark LT. Improving compliance and increasing control of blood hypertension: needs of special populations. Am Heart J 1991; 121: 664–9PubMedCrossRefGoogle Scholar
  38. 38.
    Shea A, Misra D, Ehrlich MH, et al. Predisposing factors for severe, uncontrolled hypertension in an inner-city minority population. N Engl J Med 1992; 327: 776–81PubMedCrossRefGoogle Scholar
  39. 39.
    Dustan HP, De Leon AC, Hill MN, et al. Report of the task force on the availability of cardiovascular drugs to the medically indigent. Circulation 1992; 85 (2): 849–60PubMedCrossRefGoogle Scholar
  40. 40.
    Haywood LJ. Hypertension in minority populations: access to care. Am J Med 1990; 88 Suppl. 3B: 17S-20SCrossRefGoogle Scholar
  41. 41.
    Feder G. Which guidelines to follow? BMJ 1994; 308: 470–1CrossRefGoogle Scholar
  42. 42.
    Menard J. Oil and water? Economic advantage and biomedical progress do not mix well in a government guidelines committee. Am J Hypertens 1994; 7: 877–85PubMedGoogle Scholar
  43. 43.
    Tobian L, Brunner HR, Cohn JN, et al. Modem strategies to prevent coronary sequelae and stroke in hypertensive patients differ from the JNC V consensus guidelines. Am J Hypertens 1994; 7: 859–72PubMedGoogle Scholar
  44. 44.
    Weber MA, Laragh JH. Hypertension: steps forward and steps backward. Arch Intern Med 1993; 153: 149–52PubMedCrossRefGoogle Scholar
  45. 45.
    Gavras H, Gavras I. On the JNC V report: a different point of view. Am J Hypertens 1994; 7: 288–93PubMedGoogle Scholar
  46. 46.
    Swales JD. Guidelines on guidelines. J Hypertens 1993; 11: 899–903PubMedCrossRefGoogle Scholar
  47. 47.
    Swales JD. Guidelines for treating hypertension: improved care or retarded progress. Am J Hypertens 1994; 7: 873–6PubMedGoogle Scholar
  48. 48.
    Strasser T. Relative costs of antihypertensive drug treatment. J Hum Hypertens 1992; 6: 489–94PubMedGoogle Scholar
  49. 49.
    Menard J, Cornu P, Day M. Cost of hypertension treatment and the cost of health. J Hum Hypertens 1992; 6: 447–58PubMedGoogle Scholar
  50. 50.
    Oparil S. Antihypertensive therapy: efficacy and quality of life [editorial]. N Engl J Med 1993; 328 (13): 959–61PubMedCrossRefGoogle Scholar
  51. 51.
    Cramer JA, Mattson RH, Prevey ML, et al. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989; 261: 3273–7PubMedCrossRefGoogle Scholar
  52. 52.
    Winklund I. Quality of life and cost-effectiveness in the treatment of hypertension. J Clin Pharm Ther 1994; 19 (2): 81–7CrossRefGoogle Scholar
  53. 53.
    Testa MA, Anderson RB, Nackley JF, et al. Quality of life and antihypertensive therapy in men. N Engl J Med 1993; 328 (13): 907–13PubMedCrossRefGoogle Scholar
  54. 54.
    Croog SH, Elias MF, Colton T, et al. Effects of antihypertensive medications on quality of life in elderly hypertensive women. Am J Hypertens 1994; 7: 329–39PubMedGoogle Scholar
  55. 55.
    Applegate WB, Phillips HL, Schnaper H, et al. A randomized controlled trial of the effects of three antihypertensive agents on blood pressure control and quality of life in older women. Arch Intern Med 1991; 151: 1817–23PubMedCrossRefGoogle Scholar
  56. 56.
    Skaer TL. Applying pharmacoeconomic and quality-of-life measures to the formulary management process. Hosp Formul 1993; 28 (6): 577–84PubMedGoogle Scholar
  57. 57.
    Cramer MP, Saks SR. Translating safety, efficacy and compliance into economic value for controlled release dosage forms. PharmacoEconomics 1994; 5 (6): 482–504PubMedCrossRefGoogle Scholar
  58. 58.
    Maxwell MH, Frishman WH, Kong BW. Quality-of-life considerations for first-line antihypertensive therapy. Cardiovasc Rev Rep 1994; 15: 17–22Google Scholar
  59. 59.
    Pool JL. Newer antihypertensive drugs: a glimpse into the future. Curr Opin Cardiol 1993; 8: 775–9CrossRefGoogle Scholar
  60. 60.
    Weber MA. Clinical experience with the angiotensin II receptor antagonist losartan: a preliminary report. Am J Hypertens 1992; 5 (12 Pt 2): 247S-51SGoogle Scholar
  61. 61.
    Drummond M, Coyle D. Assessing the economic value of antihypertensive medicines. J Hum Hypertens 1992; 6 (6): 495–501PubMedGoogle Scholar
  62. 62.
    Maynard A. The economics of hypertension control: some basic issues. J Hum Hypertens 1992; 6 (6): 417–20PubMedGoogle Scholar
  63. 63.
    Kozma CM, Reeder CE, Lingle EW. Expanding medicaid drug formulary coverage: effects on utilization of related services. Med Care 1990; 28 (10): 963–77PubMedCrossRefGoogle Scholar
  64. 64.
    Sclar DA, Skaer TL. Pharmaceutical formulation and healthcare expenditures. PharmacoEconomics 1992; 2 (4): 267–9PubMedCrossRefGoogle Scholar
  65. 65.
    Vageloos PR. Are prescription drug prices high? Science 1991; 252: 1080–4CrossRefGoogle Scholar
  66. 66.
    Shulman NB, Levinson RM, Dever GE, et al. Impact of cost problems on morbidity in a hypertensive population. Am J Prev Med 1991; 7 (6): 374–8PubMedGoogle Scholar

Copyright information

© Adis International Limited 1996

Authors and Affiliations

  • Tracy L. Skaer
    • 1
  • David A. Sclar
    • 1
  • Linda M. Robison
    • 1
  1. 1.College of PharmacyWashington State UniversityPullmanUSA

Personalised recommendations